New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
05:52 EDTINOInovio announces reverse stock split to commence on June 5
Inovio Pharmaceuticals announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, and trading of the company's common stock on a post-reverse split basis shall commence on Friday, June 6. The common stock will continue to trade under the symbol "INO."
News For INO From The Last 14 Days
Check below for free stories on INO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
11:15 EDTINOInovio upgraded to Buy from Hold at Aegis
Aegis upgraded Inovio to Buy following positive top-line data from the clinical trial of its lead human papillomavirus DNA-based vaccine, VGX-3100, in patients with high-grade cervical dysplasia. Price target raised to $19 from $10.
10:26 EDTINOOptions with decreasing implied volatility
Subscribe for More Information
July 23, 2014
16:47 EDTINOInovio files $175M mixed securities shelf
13:21 EDTINOInovio says ITT analysis achieved statistical significance in VGX-3100 trial
Subscribe for More Information
11:21 EDTINOOptions with decreasing implied volatility
Options with decreasing implied volatility: INO SHPG IRBT CMG LXK PSEC CROX ATHN VMW
11:08 EDTINOHigh option volume stocks
Subscribe for More Information
09:44 EDTINOInovio price target raised to $29 from $26 at Piper Jaffray
Subscribe for More Information
09:20 EDTINOInovio's VGX-3100 for cervical dysplasia shows positive Phase II results
Inovio Pharmaceuticals announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 associated with human papillomavirus types 16 or 18. Treatment with VGX-3100 resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study's primary endpoint. The trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received placebo.
July 21, 2014
07:11 EDTINOInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
July 11, 2014
11:31 EDTINOOptions with increasing implied volatility
Options with increasing implied volatility: INO AEGR UBNT INVN WTW OREX GNC CREE SD SAN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use